These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 17880274)

  • 1. Nucleoside analogue delivery systems in cancer therapy.
    Diab R; Degobert G; Hamoudeh M; Dumontet C; Fessi H
    Expert Opin Drug Deliv; 2007 Sep; 4(5):513-31. PubMed ID: 17880274
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical pharmacokinetics of nucleoside analogues: focus on haematological malignancies.
    Johnson SA
    Clin Pharmacokinet; 2000 Jul; 39(1):5-26. PubMed ID: 10926348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymer-based nanoparticles for the delivery of nucleoside analogues.
    Hillaireau H; Le Doan T; Couvreur P
    J Nanosci Nanotechnol; 2006; 6(9-10):2608-17. PubMed ID: 17048470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nanomedicine strategies for hematological malignancies: what is next?
    Visani G; Loscocco F; Isidori A
    Nanomedicine (Lond); 2014 Oct; 9(15):2415-28. PubMed ID: 25413858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
    Lech-Maranda E; Korycka A; Robak T
    Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendrimers as nanocarriers for nucleoside analogues.
    Gorzkiewicz M; Klajnert-Maculewicz B
    Eur J Pharm Biopharm; 2017 May; 114():43-56. PubMed ID: 28089915
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prodrugs of nucleoside analogues for improved oral absorption and tissue targeting.
    Li F; Maag H; Alfredson T
    J Pharm Sci; 2008 Mar; 97(3):1109-34. PubMed ID: 17696166
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug resistance to cytotoxic nucleoside analogues.
    Jordheim L; Galmarini CM; Dumontet C
    Curr Drug Targets; 2003 Aug; 4(6):443-60. PubMed ID: 12866659
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prodrugs as drug delivery system in oncology.
    Delahousse J; Skarbek C; Paci A
    Cancer Chemother Pharmacol; 2019 Nov; 84(5):937-958. PubMed ID: 31392391
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delivery of high levels of anti-proliferative nucleoside triphosphates to CYP3A-expressing cells as a potential treatment for hepatocellular carcinoma.
    MacKenna DA; Montag A; Boyer SH; Linemeyer DL; Erion MD
    Cancer Chemother Pharmacol; 2009 Oct; 64(5):981-91. PubMed ID: 19283354
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapeutic potential of novel non-toxic nucleoside analogues on EAC ascitic tumour cells.
    Barua A; Choudhury P; Maity JK; Mandal SB; Mandal S; Saha P
    Free Radic Res; 2019 Jan; 53(1):57-67. PubMed ID: 30624093
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prodrugs of Nucleoside Triphosphates as a Sound and Challenging Approach: A Pioneering Work That Opens a New Era in the Direct Intracellular Delivery of Nucleoside Triphosphates.
    Camarasa MJ
    ChemMedChem; 2018 Sep; 13(18):1885-1889. PubMed ID: 30152096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nanoscale drug delivery for targeted chemotherapy.
    Xin Y; Huang Q; Tang JQ; Hou XY; Zhang P; Zhang LZ; Jiang G
    Cancer Lett; 2016 Aug; 379(1):24-31. PubMed ID: 27235607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translocation of nucleoside analogs across the plasma membrane in hematologic malignancies.
    Fernández-Calotti PX; Colomer D; Pastor-Anglada M
    Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1324-40. PubMed ID: 22132993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prodrug-based nanoparticulate drug delivery strategies for cancer therapy.
    Luo C; Sun J; Sun B; He Z
    Trends Pharmacol Sci; 2014 Nov; 35(11):556-66. PubMed ID: 25441774
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent developments to improve the efficacy of cytotoxic nucleoside analogues.
    Jordheim LP; Galmarini CM; Dumontet C
    Recent Pat Anticancer Drug Discov; 2006 Jun; 1(2):163-70. PubMed ID: 18221034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Overcoming the delivery barrier of oligonucleotide drugs and enhancing nucleoside drug efficiency: The use of nucleolipids.
    Zhou X; Wang S; Zhu Y; Pan Y; Zhang L; Yang Z
    Med Res Rev; 2020 Jul; 40(4):1178-1199. PubMed ID: 31820472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 15 years of ATTEMPTS: a macromolecular drug delivery system based on the CPP-mediated intracellular drug delivery and antibody targeting.
    Ye J; Shin MC; Liang Q; He H; Yang VC
    J Control Release; 2015 May; 205():58-69. PubMed ID: 25483423
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.